CClinicalTrials.gg
CompletedNCT01204619TEACHUpdated Apr 14, 2016

Trial on Education And Clinical Outcomes for Home PD Patients (TEACH)

An interventional study of Intensive training group in Risk Reduction, sponsored by Kook-Hwan Oh. Completed at 6 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-04-14.

Sponsored by Kook-Hwan Oh · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

Since the emergence of home peritoneal dialysis as an alternative to in-center hemodialysis for chronic renal replacement therapy in the late 1970s, the percentage of dialysis patients on PD has continued to decrease each year. There have been a growing concern and research on patient and technique survival of peritoneal dialysis versus hemodialysis to find influential factors for better clinical outcomes. Meanwhile, technique failure rates were significantly higher in small centers treating less than twenty five PD patients. And there was a result for better technique survival after the second year, among the patients trained at the BREC(Baxter Renal Education Center). Better technique survival in large centers can be assumed with not only their more experience with patient management but also their educational infrastructure compared to small-sized centers.

Throughout our experiences in the last 30 years, we have recognized that a major element of PD program is patient training, however few data are available in terms of the relationship between PD training and treatment outcome and mostly are retrospective and non-randomized. Moreover, the technique survival and patient survival were analyzed with no significant difference.

From the insight, we decided to study prospectively to evaluate the efficacy of well-structured education program in terms of various patient outcomes in incident patients on PD.

Read the detailed description

This study will be conducted as multi-center, open-label, randomized, controlled trial. One hundred four patient starting PD will be randomized into two training groups. Patients in the conventional training group (CG) will be given non-standardized in-center conventional training programs plus two sessions of training by home visit, while those in intensive training group (IG) given in-center conventional training programs plus repeated home visits regularly over 24-month period (total thirteen visits). The primary end point of the study is exit site infection (ESI). Secondary endpoints are peritonitis and all-cause infection. Generalized Estimating Equations will be used to assess the adjusted effect of training level on the ESI and Cox regression model employed to evaluate the effect on the peritonitis and other secondary outcomes.

02

Conditions studied

  • Risk Reduction

Keywords

  • peritoneal dialysis
03

In context

Lead sponsor

This is the only study on the registry with Kook-Hwan Oh as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Incident patients who have PD catheter insertion for starting PD with Baxter solutions
  • > 20 yr of age

Exclusion criteria

Exclusion Criteria:

  • Patients who have undergone dialysis or received kidney transplant (note, however, that patients who are currently undergoing emergency hemodialysis temporarily right before the PD do not fall under the exclusion criteria.)
  • Patients who are likely to receive kidney transplant or shift to hemodialysis within the following 1 year
  • Patients diagnosed with acute inflammatory disease for the past three months
  • Patients currently diagnosed with chronic inflammatory disease
  • Currently pregnant or breastfeeding
  • Patients who are involved in other clinical trial within 30 days prior to enrollment
  • Patients who are currently hospitalized in care facilities such as nursing home, etc., or those who are expected to be hospitalized for the duration of the clinical test
  • Patients who cannot perform PD by themselves
  • Patients considered by the person in charge of the clinical test to have difficulty in participating in this clinical test
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • No intervention
    Conventional training group

    in-center conventional training programs + two home visits

  • Experimental
    Intensive training group

    in-center conventional training programs + an extra structured patient home visits repeatedly and regularly

    Behavioral: Intensive training group

Interventions

  • BehavioralIntensive training group

    an extra structured patient centric training program on PD technique and diet according to the developed training curriculum

06

What researchers measure

Primary outcomes

  1. Exit site infection

    Time frame: 24 months

Secondary outcomes

  1. time to the first peritonitis

    Time frame: 24 months

  2. Number of ESIs per patient-month

    Time frame: 24 months

  3. Days of hospitalization per year

    Time frame: 24 months

  4. Systolic pressure and diastolic pressure measured at every visit

    Time frame: 24 months

  5. Average number of antihypertensive medications

    Time frame: 24 months

  6. Kt/V

    Time frame: 24 months

  7. Residual renal function

    Time frame: 24 months

  8. Fluid balance score

    Time frame: 24 months

  9. Patient survival rate

    Time frame: 24 months

  10. Total medical cost

    Time frame: 24 months

  11. Total hours of education and training

    Time frame: 24 months

  12. Unplanned home visit and education by peritoneal dialysis nurse

    Time frame: 24 months

  13. Compliance score of patients

    Time frame: 24 months

  14. HbA1c only for patients with diabetes

    Time frame: 24 months

  15. Intact PTH level

    Time frame: 24 months

  16. Hemoglobin level

    Time frame: 24 months

  17. nPNA

    Time frame: 24 months

  18. QOL

    Time frame: 24 months

  19. SGA

    Time frame: 24 months

  20. K level

    Time frame: 24 months

  21. Total number of hospitalizations by cause over the last 1 and/or 2 years after the dialysis

    Time frame: 24 months

  22. Technical survival rate

    Time frame: 24 months

  23. peritonitis rate

    Time frame: 24 months

07

Study locations

6 sites
  • Wonkwang University, Sanbon Medical Center
    Gunpo, Gyeonggi-do, Korea, Republic of
  • Hallym University Sacred Hospital Puyngchon
    Anyang, Korea, Republic of
  • Gachon University Gil Hospital
    Incheon, Korea, Republic of
  • Eulji Medical Center
    Seoul, Korea, Republic of
  • Hallym University Sacred Hospital Gangdong
    Seoul, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01204619
Lead sponsor
Kook-Hwan Oh
Collaborators
Baxter Healthcare Corporation
Responsible party
Kook-Hwan Oh (Associate Professor, Seoul National University Hospital) — Sponsor-investigator
First posted
Sep 17, 2010
Start date
Dec 2010
Primary completion
Jul 2015
Completion
Mar 2016
Last update
Apr 14, 2016

Study contacts

Kook-Hwan Oh, M.D., PhD
principal investigator · Seoul National University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion